Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.97 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.97 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | HBB | P68871 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CDA | P32320 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL27715166 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL339188 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL67288 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9043997 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL339189 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL5961357 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL27878729 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL28325598 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790075-A | CNS targeting complexes and uses thereof | 达因疗法公司 | 2025-04-08 | — | — | CN | claimed |
| CN-118177148-A | Method for cultivating multi-embryo mutton sheep suitable for agriculture and animal husbandry by using Xinjiang local ewes | 新疆农垦科学院 | 2024-06-14 | — | — | CN | claimed |
| CN-117919419-A | Preventive or therapeutic agent for peripheral neuropathy or pain associated with diseases recognized as peripheral neuropathy or astrocytopathy | 田边三菱制药株式会社 | 2024-04-26 | — | — | CN | claimed |
| CN-117919420-A | Preventive or therapeutic agent for peripheral neuropathy or pain associated with diseases recognized as peripheral neuropathy or astrocytopathy | 田边三菱制药株式会社 | 2024-04-26 | — | — | CN | claimed |
| CN-117919418-A | Preventive or therapeutic agent for peripheral neuropathy or pain associated with diseases recognized as peripheral neuropathy or astrocytopathy | 田边三菱制药株式会社 | 2024-04-26 | — | — | CN | claimed |
| CN-117298092-A | Lipid compounds with odd-numbered carbons and their use as pharmaceutical compositions or nutritional supplements | 善睿圣医药保健股份有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-116096427-A | Compositions and methods for blood brain barrier delivery | 阿里亚达治疗公司 | 2023-05-09 | — | — | CN | claimed |
| CN-115813953-A | Application of mutton fat in preparing medicine for enhancing body immunity | 安徽大学 | 2023-03-21 | — | — | CN | claimed |
| CN-115802893-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115697063-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2023-02-03 | — | — | CN | claimed |
| CN-101250209-B | Alexan 5'-O-amino acid ester hydrochloride and preparation method thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2012-02-22 | — | — | CN | claimed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | claimed |
| CN-101812105-A | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL | 2010-08-25 | — | — | CN | claimed |
| CN-101250209-A | Alexan 5'-O-amino acid ester hydrochloride and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL (CN) | 2008-08-27 | — | — | CN | claimed |
| CN-1582166-A | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | CN | claimed |
| EP-0479805-A4 | DUAL FREQUENCY LASER LITHOTRIPTER | — | 1992-05-06 | — | — | EP | claimed |
| EP-0479805-A1 | DUAL FREQUENCY LASER LITHOTRIPTER | KARL STORZ ENDOSCOPY-AMERICA, INC. (US) | 1992-04-15 | — | — | EP | claimed |
| WO-1990012544-A1 | DUAL FREQUENCY LASER LITHOTRIPTER | KARL STORZ ENDOSCOPY-AMERICA, INC. (US) | 1990-11-01 | — | — | WO | claimed |
| EP-0245392-A1 | DEVICE FOR PHOTO-SURGERY IN PARTICULAR FOR KERATOTOMY OF THE CORNEA | G. RODENSTOCK INSTRUMENTE GMBH (DE) | 1987-11-19 | — | — | EP | claimed |
| WO-1987002884-A1 | DEVICE FOR PHOTO-SURGERY IN PARTICULAR FOR KERATOTOMY OF THE CORNEA | G. RODENSTOCK INSTRUMENTE GMBH (DE) | 1987-05-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | LMNA 3764/4885MTOR 713/4885THRB 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.